184 related articles for article (PubMed ID: 28799237)
1. Anticancer efficacy of the hypoxia-activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma.
Liapis V; Zysk A; DeNichilo M; Zinonos I; Hay S; Panagopoulos V; Shoubridge A; Difelice C; Ponomarev V; Ingman W; Atkins GJ; Findlay DM; Zannettino ACW; Evdokiou A
Cancer Med; 2017 Sep; 6(9):2164-2176. PubMed ID: 28799237
[TBL] [Abstract][Full Text] [Related]
2. Anticancer efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in osteolytic breast cancer murine models.
Liapis V; Zinonos I; Labrinidis A; Hay S; Ponomarev V; Panagopoulos V; Zysk A; DeNichilo M; Ingman W; Atkins GJ; Findlay DM; Zannettino AC; Evdokiou A
Cancer Med; 2016 Mar; 5(3):534-45. PubMed ID: 26749324
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia-activated pro-drug TH-302 exhibits potent tumor suppressive activity and cooperates with chemotherapy against osteosarcoma.
Liapis V; Labrinidis A; Zinonos I; Hay S; Ponomarev V; Panagopoulos V; DeNichilo M; Ingman W; Atkins GJ; Findlay DM; Zannettino ACW; Evdokiou A
Cancer Lett; 2015 Feb; 357(1):160-169. PubMed ID: 25444931
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in nasopharyngeal carcinoma in vitro and in vivo.
Huang Y; Tian Y; Zhao Y; Xue C; Zhan J; Liu L; He X; Zhang L
Cancer Commun (Lond); 2018 May; 38(1):15. PubMed ID: 29764490
[TBL] [Abstract][Full Text] [Related]
5. Comparison of hypoxia-activated prodrug evofosfamide (TH-302) and ifosfamide in preclinical non-small cell lung cancer models.
Sun JD; Liu Q; Ahluwalia D; Ferraro DJ; Wang Y; Jung D; Matteucci MD; Hart CP
Cancer Biol Ther; 2016 Apr; 17(4):371-80. PubMed ID: 26818215
[TBL] [Abstract][Full Text] [Related]
6. Combined Antitumor Therapy with Metronomic Topotecan and Hypoxia-Activated Prodrug, Evofosfamide, in Neuroblastoma and Rhabdomyosarcoma Preclinical Models.
Zhang L; Marrano P; Wu B; Kumar S; Thorner P; Baruchel S
Clin Cancer Res; 2016 Jun; 22(11):2697-708. PubMed ID: 26719428
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia-Activated Prodrug Evofosfamide Treatment in Pancreatic Ductal Adenocarcinoma Xenografts Alters the Tumor Redox Status to Potentiate Radiotherapy.
Kishimoto S; Brender JR; Chandramouli GVR; Saida Y; Yamamoto K; Mitchell JB; Krishna MC
Antioxid Redox Signal; 2021 Oct; 35(11):904-915. PubMed ID: 32787454
[No Abstract] [Full Text] [Related]
8. Radiotherapy Synergizes with the Hypoxia-Activated Prodrug Evofosfamide: In Vitro and In Vivo Studies.
Takakusagi Y; Kishimoto S; Naz S; Matsumoto S; Saito K; Hart CP; Mitchell JB; Krishna MC
Antioxid Redox Signal; 2018 Jan; 28(2):131-140. PubMed ID: 28741367
[TBL] [Abstract][Full Text] [Related]
9. An Intratumor Pharmacokinetic/Pharmacodynamic Model for the Hypoxia-Activated Prodrug Evofosfamide (TH-302): Monotherapy Activity is Not Dependent on a Bystander Effect.
Hong CR; Wilson WR; Hicks KO
Neoplasia; 2019 Feb; 21(2):159-171. PubMed ID: 30591421
[TBL] [Abstract][Full Text] [Related]
10. Cellular pharmacology of evofosfamide (TH-302): A critical re-evaluation of its bystander effects.
Hong CR; Dickson BD; Jaiswal JK; Pruijn FB; Hunter FW; Hay MP; Hicks KO; Wilson WR
Biochem Pharmacol; 2018 Oct; 156():265-280. PubMed ID: 30134191
[TBL] [Abstract][Full Text] [Related]
11. Administration of Hypoxia-Activated Prodrug Evofosfamide after Conventional Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Preclinical Models of Colorectal Cancer.
Haynes J; McKee TD; Haller A; Wang Y; Leung C; Gendoo DMA; Lima-Fernandes E; Kreso A; Wolman R; Szentgyorgyi E; Vines DC; Haibe-Kains B; Wouters BG; Metser U; Jaffray DA; Smith M; O'Brien CA
Clin Cancer Res; 2018 May; 24(9):2116-2127. PubMed ID: 29476017
[No Abstract] [Full Text] [Related]
12. The hypoxia-activated prodrug evofosfamide in combination with multiple regimens of radiotherapy.
Nytko KJ; Grgic I; Bender S; Ott J; Guckenberger M; Riesterer O; Pruschy M
Oncotarget; 2017 Apr; 8(14):23702-23712. PubMed ID: 28423594
[TBL] [Abstract][Full Text] [Related]
13. A phase 1 'window-of-opportunity' trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients.
Larue RT; Van De Voorde L; Berbée M; van Elmpt WJ; Dubois LJ; Panth KM; Peeters SG; Claessens A; Schreurs WM; Nap M; Warmerdam FA; Erdkamp FL; Sosef MN; Lambin P
BMC Cancer; 2016 Aug; 16():644. PubMed ID: 27535748
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer.
Sun JD; Liu Q; Ahluwalia D; Li W; Meng F; Wang Y; Bhupathi D; Ruprell AS; Hart CP
Cancer Biol Ther; 2015; 16(3):438-49. PubMed ID: 25679067
[TBL] [Abstract][Full Text] [Related]
15. Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma.
Jamieson SM; Tsai P; Kondratyev MK; Budhani P; Liu A; Senzer NN; Chiorean EG; Jalal SI; Nemunaitis JJ; Kee D; Shome A; Wong WW; Li D; Poonawala-Lohani N; Kakadia PM; Knowlton NS; Lynch CR; Hong CR; Lee TW; Grénman RA; Caporiccio L; McKee TD; Zaidi M; Butt S; Macann AM; McIvor NP; Chaplin JM; Hicks KO; Bohlander SK; Wouters BG; Hart CP; Print CG; Wilson WR; Curran MA; Hunter FW
JCI Insight; 2018 Aug; 3(16):. PubMed ID: 30135316
[TBL] [Abstract][Full Text] [Related]
16. A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma.
Laubach JP; Liu CJ; Raje NS; Yee AJ; Armand P; Schlossman RL; Rosenblatt J; Hedlund J; Martin M; Reynolds C; Shain KH; Zackon I; Stampleman L; Henrick P; Rivotto B; Hornburg KTV; Dumke HJ; Chuma S; Savell A; Handisides DR; Kroll S; Anderson KC; Richardson PG; Ghobrial IM
Clin Cancer Res; 2019 Jan; 25(2):478-486. PubMed ID: 30279233
[TBL] [Abstract][Full Text] [Related]
17. Targeting Hypoxia Using Evofosfamide and Companion Hypoxia Imaging of FMISO-PET in Advanced Biliary Tract Cancer.
Yoon J; Kang SY; Lee KH; Cheon GJ; Oh DY
Cancer Res Treat; 2021 Apr; 53(2):471-479. PubMed ID: 33091966
[TBL] [Abstract][Full Text] [Related]
18. Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer.
Sun JD; Liu Q; Wang J; Ahluwalia D; Ferraro D; Wang Y; Duan JX; Ammons WS; Curd JG; Matteucci MD; Hart CP
Clin Cancer Res; 2012 Feb; 18(3):758-70. PubMed ID: 22184053
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia.
Badar T; Handisides DR; Benito JM; Richie MA; Borthakur G; Jabbour E; Harutyunyan K; Konoplev S; Faderl S; Kroll S; Andreeff M; Pearce T; Kantarjian HM; Cortes JE; Thomas DA; Konopleva M
Am J Hematol; 2016 Aug; 91(8):800-5. PubMed ID: 27169385
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of both thioredoxin reductase and glutathione reductase may contribute to the anticancer mechanism of TH-302.
Li S; Zhang J; Li J; Chen D; Matteucci M; Curd J; Duan JX
Biol Trace Elem Res; 2010 Sep; 136(3):294-301. PubMed ID: 19838642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]